Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01648205 · ClinicalTrials.gov registry record · Phase 2
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01648205 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 25 participants.
The verdict
NCT01648205, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether late sodium channel blockade might be effective in shortening the QTc interval in various LQT3 mutations and be considered as a safe therapeutic option for LQT3 patients.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-09 |
| Est. Completion | 2018-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01648205
The ClinicalTrials.gov registry entry for NCT01648205 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01648205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01648205 about?
NCT01648205 is a clinical study titled "Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients". The purpose of this study is to determine whether late sodium channel blockade might be effective in shortening the QTc interval in various LQT3 mutations and be considered as a safe therapeutic option for LQT3 patients.
What is the current status of trial NCT01648205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-09. Estimated completion is 2018-07-20.
What interventions are being tested in trial NCT01648205?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01648205?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.